151 related articles for article (PubMed ID: 32539376)
1. Targeting Peroxisome Proliferator-Activated Receptor Delta (PPARδ): A Medicinal Chemistry Perspective.
Kadayat TM; Shrestha A; Jeon YH; An H; Kim J; Cho SJ; Chin J
J Med Chem; 2020 Sep; 63(18):10109-10134. PubMed ID: 32539376
[TBL] [Abstract][Full Text] [Related]
2. Advances and Challenges in Drug Design of PPARδ Ligands.
Maltarollo VG; Kronenberger T; Windshugel B; Wrenger C; Trossini GHG; Honorio KM
Curr Drug Targets; 2018; 19(2):144-154. PubMed ID: 28413978
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and structure-activity relationship study of peroxisome proliferator-activated receptor (PPAR) delta-selective ligands.
Miyachi H
Curr Med Chem; 2007; 14(22):2335-43. PubMed ID: 17896982
[TBL] [Abstract][Full Text] [Related]
4. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
[TBL] [Abstract][Full Text] [Related]
5. [Design and synthesis of peroxisome proliferator-activated receptor (PPAR) delta agonists and its implication to the driving force to elicit PPAR delta selectivity].
Kasuga J; Oyama T; Nakagome I; Aoyama A; Sako K; Makishima M; Hirono S; Morikawa K; Hashimoto Y; Miyachi H
Yakugaku Zasshi; 2009 Jun; 129(6):709-18. PubMed ID: 19483413
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and SAR of selective benzothiophene, benzofuran, and indole-based peroxisome proliferator-activated receptor delta agonists.
Filzen GF; Bratton L; Cheng XM; Erasga N; Geyer A; Lee C; Lu G; Pulaski J; Sorenson RJ; Unangst PC; Trivedi BK; Xu X
Bioorg Med Chem Lett; 2007 Jul; 17(13):3630-5. PubMed ID: 17512197
[TBL] [Abstract][Full Text] [Related]
7. Discovery of highly potent and selective benzyloxybenzyl-based peroxisome proliferator-activator receptor (PPAR) delta agonists.
Bratton LD; Filzen GF; Geyer A; Hoffman JK; Lu G; Pulaski J; Trivedi BK; Unangst PC; Xu X
Bioorg Med Chem Lett; 2007 Jul; 17(13):3624-9. PubMed ID: 17498950
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present).
Takada I; Makishima M
Expert Opin Ther Pat; 2020 Jan; 30(1):1-13. PubMed ID: 31825687
[No Abstract] [Full Text] [Related]
9. Recent Updates on Peroxisome Proliferator-Activated Receptor δ Agonists for the Treatment of Metabolic Syndrome.
Grewal AS; Beniwal M; Pandita D; Sekhon BS; Lather V
Med Chem; 2016; 12(1):3-21. PubMed ID: 26004782
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) delta-selective agonists.
Kasuga J; Nakagome I; Aoyama A; Sako K; Ishizawa M; Ogura M; Makishima M; Hirono S; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2007 Aug; 15(15):5177-90. PubMed ID: 17532641
[TBL] [Abstract][Full Text] [Related]
11. Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome.
Li Z; Ren Q; Zhou Z; Cai Z; Wang B; Han J; Zhang L
Eur J Med Chem; 2021 Dec; 225():113807. PubMed ID: 34455359
[TBL] [Abstract][Full Text] [Related]
12. Discovery and structure-activity relationship study of 2-piperazinyl-benzothiazole derivatives as potent and selective PPARδ agonists.
Kato T; Ohara T; Suzuki N; Naya N; Fukao K; Tokuyama R; Muto S; Fukasawa H; Itai A; Matsumura KI
Bioorg Med Chem; 2023 Mar; 82():117215. PubMed ID: 36840990
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationship studies of non-carboxylic acid peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
Okazaki S; Shioi R; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
Bioorg Med Chem; 2016 Nov; 24(21):5455-5461. PubMed ID: 27622746
[TBL] [Abstract][Full Text] [Related]
14. Identification and Molecular Characterization of Peroxisome Proliferator-Activated Receptor δ as a Novel Target for Covalent Modification by 15-Deoxy-Δ
Reddy AT; Lakshmi SP; Banno A; Reddy RC
ACS Chem Biol; 2018 Dec; 13(12):3269-3278. PubMed ID: 30398845
[TBL] [Abstract][Full Text] [Related]
15. Novel biphenylcarboxylic acid peroxisome proliferator-activated receptor (PPAR) delta selective antagonists.
Kasuga J; Ishida S; Yamasaki D; Makishima M; Doi T; Hashimoto Y; Miyachi H
Bioorg Med Chem Lett; 2009 Dec; 19(23):6595-9. PubMed ID: 19853439
[TBL] [Abstract][Full Text] [Related]
16. Design and Structural Optimization of Dual FXR/PPARδ Activators.
Schierle S; Neumann S; Heitel P; Willems S; Kaiser A; Pollinger J; Merk D
J Med Chem; 2020 Aug; 63(15):8369-8379. PubMed ID: 32687365
[TBL] [Abstract][Full Text] [Related]
17. A novel peroxisome proliferator response element modulates hepatic low-density lipoprotein receptor gene transcription in response to PPARδ activation.
Shende VR; Singh AB; Liu J
Biochem J; 2015 Dec; 472(3):275-86. PubMed ID: 26443862
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor delta (PPARdelta), a novel target site for drug discovery in metabolic syndrome.
Takahashi S; Tanaka T; Kodama T; Sakai J
Pharmacol Res; 2006 Jun; 53(6):501-7. PubMed ID: 16713711
[TBL] [Abstract][Full Text] [Related]
19. Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
Shioi R; Okazaki S; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
Bioorg Med Chem Lett; 2017 Jul; 27(14):3131-3134. PubMed ID: 28539218
[TBL] [Abstract][Full Text] [Related]
20. Minor structural modifications convert a selective PPARalpha agonist into a potent, highly selective PPARdelta agonist.
Weigand S; Bischoff H; Dittrich-Wengenroth E; Heckroth H; Lang D; Vaupel A; Woltering M
Bioorg Med Chem Lett; 2005 Oct; 15(20):4619-23. PubMed ID: 16115765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
